Spots Global Cancer Trial Database for peritoneal neoplasms
Every month we try and update this database with for peritoneal neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | NCT03976999 | Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop... | Biological coll... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 | Gynecologic Can... Gynecologic Neo... Peritoneal Carc... Peritoneal Neop... Ovarian Cancer Ovarian Neoplas... Colorectal Canc... Colorectal Neop... Appendiceal Can... Appendiceal Neo... | Paclitaxel Nilotinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| DNA Single Nucleotide Polymorphisms as Predictors of Toxicity | NCT02478476 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | 18 Years - | OvaGene Oncology, Inc. | ||
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers | NCT00666991 | Peritoneal Neop... | nanoparticulate... | 18 Years - | CritiTech, Inc. | |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | NCT03740165 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Pembrolizumab Placebo for pem... Carboplatin Paclitaxel Olaparib Placebo for ola... Bevacizumab Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | NCT00074867 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | CP-547,632 | 18 Years - | Pfizer | |
| Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | NCT00318370 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Farletuzumab Chemo Plus Far | 18 Years - | Morphotek | |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | NCT03593681 | Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease... | Hysteroscopic c... | 18 Years - | Boston Scientific Corporation | |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT01932125 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | NCT00191646 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | NCT00112086 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Neoadjuvant che... | 20 Years - 75 Years | Japan Clinical Oncology Group | |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | NCT00035100 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | epothilone b | 18 Years - | Novartis | |
| Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | NCT00517621 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Paclitaxel EPO | 18 Years - | ARCAGY/ GINECO GROUP | |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | NCT04498117 | Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop... | Oregovomab Paclitaxel Carboplatin Placebo Carboplatin | 18 Years - | CanariaBio Inc. | |
| Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | NCT00183794 | Ovarian Carcino... Peritoneal Neop... | Docetaxel and G... | 18 Years - | University of Southern California | |
| Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | NCT00968799 | Epithelial Ovar... Fallopian Tube ... | Hyperthermic in... Cytoreduction Cisplatin | 18 Years - 70 Years | Cantonal Hospital of St. Gallen | |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00382811 | Fallopian Tube ... Peritoneal Neop... Ovarian Cancer | phenoxodiol carboplatin placebo | 18 Years - | MEI Pharma, Inc. | |
| An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA) | NCT01697488 | Peritoneal Neop... | 18 Years - | Hoffmann-La Roche | ||
| Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | NCT00216372 | Intestinal Obst... Carcinoma Peritoneal Neop... | Lanreotide (mic... Placebo | 18 Years - | Ipsen | |
| Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | NCT00216372 | Intestinal Obst... Carcinoma Peritoneal Neop... | Lanreotide (mic... Placebo | 18 Years - | Ipsen | |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | NCT00443196 | Adenocarcinoma Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | MiCK Assay | - | Pierian Biosciences | |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | NCT00443196 | Adenocarcinoma Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | MiCK Assay | - | Pierian Biosciences | |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | NCT04111978 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... High-grade Sero... Low-grade Serou... Ovarian Endomet... | Letrozole 2.5mg Placebo | 18 Years - | Swiss GO Trial Group | |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT01932125 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | NCT03976999 | Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop... | Biological coll... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | NCT01681368 | Epithelial Ovar... Peritoneal Neop... Fallopian Tube ... | Birinapant (TL3... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | NCT01015118 | Ovarian Neoplas... Peritoneal Neop... | Placebo Paclitaxel BIBF 1120 Carboplatin Paclitaxel Carboplatin | 18 Years - | Boehringer Ingelheim | |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | NCT00191646 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis | NCT00216372 | Intestinal Obst... Carcinoma Peritoneal Neop... | Lanreotide (mic... Placebo | 18 Years - | Ipsen | |
| OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer | NCT00382811 | Fallopian Tube ... Peritoneal Neop... Ovarian Cancer | phenoxodiol carboplatin placebo | 18 Years - | MEI Pharma, Inc. | |
| Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | NCT00332696 | Peritoneal Neop... Intestinal Obst... Carcinomatosis | Octreotide LAR Octreotide (Imm... methylprednisol... Placebo | 18 Years - | Novartis | |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | NCT00191646 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | NCT01462890 | Genital Disease... Ovarian Disease... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Bevacizumab Paclitaxel Carboplatin specialized pat... | 18 Years - | AGO Study Group | |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | NCT00262990 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | EPO906 (Patupil... doxorubicin | 18 Years - | Novartis | |
| BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer | NCT01314105 | Ovarian Neoplas... Peritoneal Neop... | BIBF 1120 + PLD... BIBF 1120+ PLD ... BIBF 1120 + PLD... | 18 Years - | Boehringer Ingelheim | |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | NCT02571725 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Olaparib Tremelimumab | 18 Years - | New Mexico Cancer Care Alliance | |
| Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | NCT01384253 | Breast Neoplasm... Peritoneal Neop... Ovarian Neoplas... Pancreatic Neop... Stomach Neoplas... | ²¹²Pb-TCMC-Tras... trastuzumab | 19 Years - | Orano Med LLC | |
| Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT | NCT02638051 | Peritoneal Neop... Ascites Yang Deficiency Yin Deficiency | Modulated Elect... TCM Herbal Deco... IPCI (CDDP+5FU) | 18 Years - 75 Years | Galenic Research Institute Ltd | |
| BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer | NCT01314105 | Ovarian Neoplas... Peritoneal Neop... | BIBF 1120 + PLD... BIBF 1120+ PLD ... BIBF 1120 + PLD... | 18 Years - | Boehringer Ingelheim | |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | NCT02571725 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Olaparib Tremelimumab | 18 Years - | New Mexico Cancer Care Alliance | |
| Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | NCT02903771 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Part A: Dose Es... Part B: Expansi... | 18 Years - | Kazia Therapeutics Limited | |
| Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin | NCT00502177 | Peritoneal Neop... | Questionnaire | 1 Year - 18 Years | M.D. Anderson Cancer Center | |
| Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | NCT00103545 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | ACA 125 | 0 Years - | AGO Study Group | |
| Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | NCT05353582 | Colorectal Neop... Colorectal Canc... Colorectal Canc... Peritoneal Meta... Peritoneal Canc... Peritoneal Neop... Chemotherapy Ef... Cytoreductive S... Hyperthermic In... | Preoperative sy... CRS+HIPEC Postoperative c... Postoperative c... | 18 Years - 75 Years | Sun Yat-sen University | |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | NCT00407407 | Fallopian Tube ... Peritoneal Neop... Ovarian Neoplas... | ABI-007 Carboplatin | 18 Years - | Celgene | |
| Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | NCT00262990 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | EPO906 (Patupil... doxorubicin | 18 Years - | Novartis | |
| Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | NCT02758951 | Colorectal Neop... Colorectal Canc... Colorectal Neop... Colorectal Carc... Colorectal Aden... Peritoneal Neop... Peritoneal Carc... Peritoneal Canc... Peritoneal Meta... Peritoneal Neop... Peritoneal Neop... | Perioperative s... Perioperative C... Perioperative F... Perioperative F... CRS-HIPEC, expe... CRS-HIPEC, cont... | 18 Years - | Catharina Ziekenhuis Eindhoven | |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | NCT00086567 | Fallopian Tube ... Peritoneal Neop... Epithelial Ovar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | NCT00698451 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | doxorubicin HCL... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | NCT02578888 | Cervical Carcin... Ovarian Carcino... Primary Periton... Recurrent Cervi... Recurrent Ovari... Recurrent Uteri... Recurrent Vulva... Uterine Corpus ... Vulvar Carcinom... Peritoneal Neop... | Palliative Ther... Palliative Ther... | - | Albert Einstein College of Medicine | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00288275 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | 18 Years - | Precision Therapeutics | ||
| Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy | NCT06351475 | Peritoneal Neop... Hyperthermic In... Intraoperative ... Fluid Therapy Postoperative C... | Intra-operative... Control | 18 Years - 80 Years | Assistance Publique - Hôpitaux de Paris | |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | NCT00326885 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | NCT03593681 | Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease... | Hysteroscopic c... | 18 Years - | Boston Scientific Corporation | |
| Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | NCT00436657 | Peritoneal Neop... Retroperitoneal... Gastrointestina... Adenocarcinoma Neuroblastoma Ovarian Neoplas... Sarcoma Adrenocortical ... Wilms Tumor Rhabdomyosarcom... Desmoplastic Sm... | CHPP of Cisplat... Abdominal Surge... | 3 Years - 18 Years | M.D. Anderson Cancer Center | |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03038100 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Paclitaxel Carboplatin Atezolizumab Bevacizumab Atezolizumab Pl... | 18 Years - | Hoffmann-La Roche | |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | NCT00086567 | Fallopian Tube ... Peritoneal Neop... Epithelial Ovar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | NCT01478685 | Urinary Bladder... Carcinoma, Tran... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... Carcinoma, Non-... Carcinoma, Panc... Tumor Virus Inf... | CC-486 Carboplatin ABI-007 | 18 Years - | Celgene | |
| Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC | NCT01225757 | Peritoneal Neop... Echocardiograph... | Echocardiogram | 19 Years - | University of Nebraska | |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | NCT00086567 | Fallopian Tube ... Peritoneal Neop... Epithelial Ovar... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | NCT00191607 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | NCT00189345 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | anti-EpCAM x an... | 18 Years - | AGO Study Group | |
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00288275 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | 18 Years - | Precision Therapeutics | ||
| OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | NCT00112086 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Neoadjuvant che... | 20 Years - 75 Years | Japan Clinical Oncology Group | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy - | NCT03287375 | Peritoneum; Car... Peritoneal Neop... Peritoneal Meta... Chemotherapy Ef... Chemotherapeuti... Quality of Life Histologic Prog... | PIPAC | 18 Years - | Odense University Hospital | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
